PledPharma receives 500,000 SEK in VINNOVA financing
April 3, 2012
PledPharma AB Company Announcement PledPharma receives 500,000 SEK in VINNOVA financing Vinnova has decided to give PledPharma AB 500,000 SEK in financing from the “Forska & Väx” (Research & Grow) program. Stockholm, 2012-04-03 15:30 CEST (GLOBE NEWSWIRE) -- The financing will be used for preclinical studies to widen the PledOx project to also encompass side-effects during other cancer treatment than colorectal cancer treatment. For further information please contact: Jacques Näsström, CEO, cell: +46 73 713 0979 About PledPharma PledPharma is a Swedish specialty pharma company, which develops new treatments of life threatening diseases. PledPharma currently runs two projects in clinical development phase II with the patented drug substance class, PLED-derivatives. The preventive effect of PLED-derivatives on adverse effects of chemotherapy in colon cancer is examined in one trial. Another trial investigates the ability of PLED-derivatives to reduce reperfusion injuries in myocardial infarction patients undergoing percutaneous coronary intervention (PCI). PLED-derivatives protect the body’s normal cells against oxidative stress, which is a condition due to overproduction of free oxygen radicals. PLED-derivatives have in previous pre-clinical trials been shown to protect against oxidative stress. Moreover, the PLED-derivative mangafodipir protected against the side effects of chemotherapy in colorectal cancer. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For more information, please visit www.pledpharma.se
